Online inquiry

IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1395MR)

This product GTTS-WQ1395MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL1A&IL1B gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5; NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552; 3553
UniProt ID P01583; P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1395MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14748MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ11790MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ12607MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ6279MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ12524MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ8132MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ416MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ15942MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW